QL1706

Dr. Shu's phase II study in advanced hepatocellular carcinoma reports encouraging response rates and median progression-free survival with QL1706, a bifunctional antibody combining anti-PD-1 and anti-CTLA-4 with reduced toxicity. The study, involving 120 patients, compared QL1706 in various combinations, including with chemotherapy and bevacizumab, showing higher response rates than control arms. The study's relevance to patients with liver dysfunction remains unclear, but QL1706's potential to facilitate triplet combinations with less toxicity is promising.